OverviewSuggest Edit

Perrigo Company plc, a top five global over-the-counter (OTC) consumer goods and pharmaceutical company, offers consumers and customers high quality products at affordable prices. From its beginnings in 1887 as a packager of generic home remedies, Perrigo, headquartered in Ireland, has grown to become the world's largest manufacturer of OTC products and supplier of infant formulas for the store brand market. The Company is also a leading provider of branded OTC products, generic extended topical prescription products and receives royalties from Multiple Sclerosis drug Tysabri®. Perrigo provides “Quality Affordable Healthcare Products®” across a wide variety of product categories and geographies primarily in North America, Europe, and Australia, as well as other key markets including Israel and China.

TypePublic
Founded1887
HQDublin, IE
Websiteperrigo.com
Employee Ratings3.6

Latest Updates

Employees (est.) (Dec 2019)11,200(+6%)
Job Openings121
Revenue (FY, 2019)$4.8 B(+3%)
Share Price (Oct 2020)$47.4 (+2%)
Cybersecurity ratingCMore

Key People/Management at Perrigo

Murray S. Kessler

Murray S. Kessler

President & Chief Executive Officer
Raymond Silcock

Raymond Silcock

Executive Vice President and Chief Financial Officer
Svend Andersen

Svend Andersen

Executive Vice President & President, Consumer Self-Care International
Ron Janish

Ron Janish

Executive Vice President of Global Operations and Supply Chain
Tom Farrington

Tom Farrington

Executive Vice President & Chief Information Officer
Todd W. Kingma

Todd W. Kingma

Executive Vice President, General Counsel and Secretary
Show more

Perrigo Office Locations

Perrigo has offices in Dublin, Allegan and Lisboa
Dublin, IE (HQ)
20-21 Pembroke Street Upper
Lisboa, PT
Lagoas Park Edificio 15 3º Piso, Porto Salvo
Allegan, US
515 Eastern Ave
Show all (3)

Perrigo Financials and Metrics

Perrigo Revenue

Embed Graph
View revenue for all periods
Perrigo's revenue was reported to be $4.84 b in FY, 2019
USD

Revenue (Q2, 2020)

1.2b

Gross profit (Q2, 2020)

434.7m

Gross profit margin (Q2, 2020), %

35.7%

Net income (Q2, 2020)

60.6m

EBIT (Q2, 2020)

117.4m

Market capitalization (16-Oct-2020)

6.5b

Closing stock price (16-Oct-2020)

47.4

Cash (27-Jun-2020)

1.5b

EV

5.6b
Perrigo's current market capitalization is $6.5 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2018FY, 2019

Revenue

4.1b4.6b5.3b4.7b4.8b

Revenue growth, %

13%(71%)

Cost of goods sold

2.6b2.9b3.2b2.9b3.1b

Gross profit

1.4b1.7b2.1b1.8b1.8b
USDQ1, 2014

Financial Leverage

-0.8 x
Show all financial metrics

Perrigo Cybersecurity Score

Cybersecurity ratingPremium dataset

C

71/100

SecurityScorecard logo

Perrigo Online and Social Media Presence

Embed Graph

Perrigo News and Updates

Perrigo shares dip premarket on news to voluntarily recall albuterol sulfate inhalation aerosols due to clogging concerns

Perrigo Company plc shares slid 3% in premarket trade Thursday, after the company said it's voluntarily recalling albuterol sulfate inhalation aerosols over concerns that some may not dispense properly due to clogging. The Dublin-based maker of over-the-counter and generic health products already h…

Perrigo Voluntarily Recalls Albuterol Sulfate Inhalation Aerosol; Reaffirms 2020 Guidance

DUBLIN, Sept. 17, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced a voluntary U.S. nationwide recall of albuterol sulfate inhalation aerosol to the retail level after previously halting production and distribution. These actions are being taken out of an...

Perrigo Announces The Store Brand Equivalent Of Voltaren® Arthritis Pain Is Available At U.S. Major Retailers Nationwide

DUBLIN, Sept. 8, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has launched the store brand equivalent of over-the-counter ("OTC") Voltaren® Arthritis Pain (diclofenac sodium topical gel, 1%) to its retail partners and the product is now available in...

Perrigo To Release Second Quarter 2020 Financial Results On August 5, 2020

DUBLIN, July 15, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced that it will release its second quarter financial results on Wednesday, August 5, 2020. The Company will also host a conference call...

Perrigo Donates 160,000 Toothbrushes to West Michigan Nonprofit Organizations

GRAND RAPIDS, Mich., June 2, 2020 /PRNewswire/ -- As organizations struggle to meet increased demand for charitable relief during the COVID-19 pandemic, Perrigo Company is donating more than 160,000 toothbrushes to Camp Fire West Michigan, The StoreHouse of Community Resources and Kids...

Perrigo sees strong sales amid coronavirus pandemic

Perrigo Co. said late Tuesday it experienced a first-quarter sales boost due to the COVID-19 pandemic. The over-the-counter drug maker said it expects adjusted operating income of $220 million to $225 million on revenue of about $1.3 billion. Analysts surveyed by FactSet expect adjusted operating i…
Show more

Perrigo Frequently Asked Questions

  • When was Perrigo founded?

    Perrigo was founded in 1887.

  • Who are Perrigo key executives?

    Perrigo's key executives are Murray S. Kessler, Raymond Silcock and Svend Andersen.

  • How many employees does Perrigo have?

    Perrigo has 11,200 employees.

  • What is Perrigo revenue?

    Latest Perrigo annual revenue is $4.8 b.

  • What is Perrigo revenue per employee?

    Latest Perrigo revenue per employee is $431.9 k.

  • Who are Perrigo competitors?

    Competitors of Perrigo include Consort Medical, Jazz Pharmaceuticals and Bausch Health Companies.

  • Where is Perrigo headquarters?

    Perrigo headquarters is located at 20-21 Pembroke Street Upper, Dublin.

  • Where are Perrigo offices?

    Perrigo has offices in Dublin, Allegan and Lisboa.

  • How many offices does Perrigo have?

    Perrigo has 3 offices.